Aequus Pharmaceuticals Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Aequus Pharmaceuticals Inc. is a Canadian specialty pharmaceutical company focused on developing and commercializing high-quality, differentiated pharmaceutical products mainly in the ophthalmology and neurology fields. The company offers products including ZIMED® PF, a preservative-free bimatoprost 0.03% ophthalmic solution approved for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Aequus is also developing REV-0100, a preclinical-stage treatment for Stargardt disease, which has received Orphan Drug and Rare Pediatric Disease designations from the US FDA. The company produces prescription pharmaceuticals, natural health products, and engages in promotional services for third-party products such as Tacrolimus IR. Aequus operates with an end-to-end commercialization platform in Canada, leveraging in-house sales and marketing infrastructure alongside partnerships to introduce and grow differentiated products within specialized therapeutic areas such as ophthalmology, neurology, and psychiatry. The company builds its portfolio primarily through in-licensing, acquisitions, and distribution agreements, aiming to expand its presence in the Canadian market while exploring strategic partnerships for broader global reach. Recent major developments include the launch of ZIMED® PF in August 2023 and its subsequent sale to Luvo Medical Technologies for CAD 0.40 million in 2024. In 2024, Aequus underwent a significant restructuring by reducing the size of its commercial sales team to lower operating expenses and financing needs, while continuing to promote ZIMED® PF through a network of external distributors and consultants. The company also continues a strategic review to explore potential transactions and alternative business opportunities. Financially, Aequus reported revenue growth attributed to increased market penetration of ZIMED® PF supported by higher promotional activities. Founded in 2013 and headquartered in Vancouver, British Columbia, Aequus Pharmaceuticals maintains a focus on specialty pharmaceutical manufacturing and commercialization in Canada with approximately 11-50 employees. The company is publicly listed on the TSX Venture Exchange under ticker AQS and OTCQB as AQSZF, serving Canadian healthcare providers and patients with a commitment to addressing unmet medical needs through innovative drug delivery and product offerings. Aequus’s leadership has significant experience in the life sciences industry, including strategic advisory and capital raising, positioning the company to expand its product pipeline and commercial reach in the years ahead. The company continues to pursue partnerships and in-licensing opportunities to strengthen its portfolio in ophthalmology and other specialized therapeutic areas in Canada and potentially North America.
Aequus Announces Completion of Previously Announced Sale of ZIMED(R) PF
Aequus Provides Additional Disclosure in Connection with Annual General and Special Meeting of Shareholders
Aequus Provides Additional Disclosure in Connection with Annual General and Special Meeting of Shareholders
Aequus Announces Giovanni Di Genova Joining Board of Directors
Aequus Reports First Quarter 2025 Financial Highlights
Aequus Reports Second Quarter 2023 Financial Highlights and General Update
Aequus Announces Zimed PF Now Available in Canada
Aequus Announces Zimed PF Website Launch
Aequus Pharmaceutical Canada Announces a Pause in Sales of Evolve Intensive Eyedrops and Gel in Canada
Aequus Announces Financing to Support Launch of Zimed Preservative Free (Bimatoprost 0.03%)
Aequus Pharmaceuticals achieves its second-highest quarterly revenue to date
Aequus Reports Second Quarter 2021 Financial Highlights
Aequus Pharmaceuticals appoints Dr. Robert Koenekoop as its consultant on inherited retinal diseases
Aequus Pharmaceuticals and reVision Therapeutics in collaboration to develop therapy for Stargardt disease
Aequus Pharmaceuticals bringing diverse pipeline of new drugs to the Canadian market
Aequus Pharmaceuticals says it will maintain commercial relationship with Sandoz into 2022
Aequus Pharmaceuticals first quarter results show good progress in spite of the coronavirus pandemic
Aequus Provides General Update and First Quarter 2021 Financial Highlights
Wall Street brushes off initial worries over potential capital gains tax hike
Aequus sees fiscal 2020 revenue rise by 59%, driven by strong sales of Vistitan and Tacrolimus